Osteoporosis - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoporosis - Pipeline Review, H1 2017, provides an overview of the Osteoporosis (Metabolic Disorders) pipeline landscape.

Osteoporosis, or thinning bones, makes bones weak and more likely to break. Risk factors for osteoporosis include aging, being female, low body weight, low sex hormones or menopause, smoking, and some medications. Signs and symptoms include back pain, caused by a fractured or collapsed vertebra, loss of height over time, a stooped posture, a bone fracture that occurs much more easily than expected. Prevention and treatment include calcium and vitamin D, exercise, and osteoporosis medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteoporosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Osteoporosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteoporosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteoporosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 6, 5, 5, 11, 57, 11 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 10 and
13 molecules, respectively.

Osteoporosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoporosis (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Osteoporosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Osteoporosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Osteoporosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Osteoporosis (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Osteoporosis (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Osteoporosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

**Table Of Content**

**Notes:**

2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Osteoporosis - Overview 10
Osteoporosis - Therapeutics Development 11
Pipeline Overview 11
Pipeline by Companies 12
Pipeline by Universities/Institutes 18
Products under Development by Companies 19
Products under Development by Universities/Institutes 25
Osteoporosis - Therapeutics Assessment 27
Assessment by Target 27
Assessment by Mechanism of Action 30
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Osteoporosis - Companies Involved in Therapeutics Development 37
Addex Therapeutics Ltd 37
Alize Pharma SAS 37
Alvogen Korea Co Ltd 38
Amgen Inc 38
Amura Holdings Ltd 39
BiologicsMD Inc 39
Bone Biologics Corp 40
Bristol-Myers Squibb Company 40
Cellmid Ltd 41
ChoDang Pharm Co Ltd 41
Chugai Pharmaceutical Co Ltd 42
Corium International Inc 42
Critical Pharmaceuticals Ltd 43
Daiichi Sankyo Company Ltd 43
ElexoPharm GmbH 44
Endoceutics Inc 44
Entera Bio Ltd 45
Enteris BioPharma Inc 45
Enzo Biochem Inc 46
F. Hoffmann-La Roche Ltd 46
Gador SA 47
GL Pharm Tech Corp 47
Glide Pharmaceutical Technologies Ltd 48
Hanmi Pharmaceuticals Co Ltd 48
Haoma Medica Ltd 49
Immunovo BV 49
Immunwork Inc 50
Intas Pharmaceuticals Ltd 50
Ipsen SA 51
Kaken Pharmaceutical Co Ltd 51
Lead Discovery Center GmbH 52
Ligand Pharmaceuticals Inc 52
Lotus Pharmaceutical Co Ltd 53
Lupin Ltd 53
Merck & Co Inc 54
Mereo Biopharma Group Plc 54
NIBEC 55
Omeros Corp 55
Oncobiologics Inc 56
Osteologix Holdings Plc 56
Paras Biopharmaceuticals Finland Oy 57
Pfenex Inc 57
PhytoHealth Corp 58
R Pharm 58
Ribomic Inc 59
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd 59
Shin Poong PharmCo Ltd 60
Sinil Pharmaceutical Co Ltd 60
Stelis Biopharma Pvt Ltd 61
Sumitomo Dainippon Pharma Co Ltd 61
Terpenoid Therapeutics Inc 62
TSH Biopharm Corporation Ltd 62
Uni-Bio Science Group Ltd 63
Viking Therapeutics Inc 63
Wroclawskie Centrum Badan EIT+ Sp z oo 64
Yooyoung Pharm Co Ltd 64
Zydus Cadila Healthcare Ltd 65
Osteoporosis - Drug Profiles 66
(acolbifene hydrochloride + prasterone) - Drug Profile 66
(cholecalciferol + raloxifene) - Drug Profile 67
(cholecalciferol + risedronate sodium) - Drug Profile 68
2-AMD - Drug Profile 69
3D-QM - Drug Profile 70
3D-QMS - Drug Profile 71
abaloparatide - Drug Profile 72
ADX-68693 - Drug Profile 80
AKR-215 - Drug Profile 81
AKR-308 - Drug Profile 82
alendronate sodium - Drug Profile 83
AM-3701 - Drug Profile 84
ARC-205 - Drug Profile 85
BCD-700 - Drug Profile 86
BMD-1111 - Drug Profile 87
BMS-777607 - Drug Profile 88
BPS-804 - Drug Profile 90
calcitonin DR - Drug Profile 92
CD-030 - Drug Profile 96
CDR-914K058 - Drug Profile 97
CDRI-99/373 - Drug Profile 98
CH-5036249 - Drug Profile 99
denosumab - Drug Profile 100
denosumab biosimilar - Drug Profile 109
denosumab biosimilar - Drug Profile 110
denosumab biosimilar - Drug Profile 111
denosumab biosimilar - Drug Profile 112
Drugs to Chelate Iron for Bone Degeneration, Postmenopausal Osteoporosis and Thalassemia - Drug Profile 113
Drugs to Modulate PPAR-Delta for Metabolic and Musculoskeletal Disorders - Drug Profile 114
DS-1501 - Drug Profile 115
eldecalcitol - Drug Profile 116
Eu-232 - Drug Profile 117
Ewha-18278 - Drug Profile 118
genipin - Drug Profile 119
HCP-1405 - Drug Profile 120
HCP-1604 - Drug Profile 121
IG-8801 - Drug Profile 122
IHBD-1 - Drug Profile 123
IPS-02001 - Drug Profile 124
KAL-671 - Drug Profile 125
KKM-0805 - Drug Profile 127
KKM-0902 - Drug Profile 128
Small Molecule for Osteoporosis - Drug Profile 171
Small Molecule to Activate sGC for Osteoporosis - Drug Profile 172
Small Molecule to Agonize Androgen Receptor for Osteoporosis - Drug Profile 173
Small Molecule to Agonize EP4 Receptor for Osteoporosis - Drug Profile 174
Small Molecule to Agonize LRP for Osteoporosis - Drug Profile 175
Small Molecule to Agonize PTH-1R for Osteoporosis - Drug Profile 176
Small Molecule to Antagonize OGR1 for Asthma, Bone Diseases, Oncology and Osteoporosis - Drug Profile 177
Small Molecule to Inhibit 17beta-HSD2 for Osteoporosis - Drug Profile 178
Small Molecule to Target GPR183 for Epstein-Barr Viral Infections and Osteoporosis - Drug Profile 179
Small Molecule to Target LGR4 for Oncology and Osteoporosis - Drug Profile 180
Small Molecule to Target Plexin-B1/Sema4D for Multiple Sclerosis and Osteoporosis - Drug Profile 181
Small Molecules for Metabolic and Musculoskeletal Disorders - Drug Profile 182
Small Molecules for Musculoskeletal and Metabolic Disorders - Drug Profile 183
Small Molecules for Osteopenia and Osteoporosis - Drug Profile 184
Small Molecules for Osteoporosis - Drug Profile 185
Small Molecules for Osteoporosis - Drug Profile 186
Small Molecules to Antagonize Calcium-Sensing Receptor for Osteoporosis - Drug Profile 188
Small Molecules to Inhibit 17Beta-HSD2 for Osteoporosis - Drug Profile 189
Small Molecules to Inhibit GGDPS for Bone Metastasis and Oncology - Drug Profile 190
Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Dermatology - Drug Profile 191
Small Molecules to Inhibit Sclerostin for Osteoporosis - Drug Profile 192
Small Molecules to Target Estrogen Receptor for Breast Cancer and Osteoporosis - Drug Profile 193
Sodium Quinate - Drug Profile 194
SP-35454 - Drug Profile 195
SR-10171 - Drug Profile 196
SR-2595 - Drug Profile 197
Synthetic Peptide for Obesity and Post Menopausal Osteoporosis - Drug Profile 198
Synthetic Peptide for Osteoporosis - Drug Profile 199
Synthetic Peptide for Osteoporosis and Bone Fracture - Drug Profile 200
Synthetic Peptides for Ischemic Stroke, Osteoporosis and Sepsis - Drug Profile 201
TE-3110 - Drug Profile 202
TE-3236 - Drug Profile 203
teriparatide - Drug Profile 204
teriparatide - Drug Profile 205
<p>| Products under Development by Companies, H1 2017 (Contd..3), H1 2017 |
| Products under Development by Companies, H1 2017 (Contd..4), H1 2017 |
| Products under Development by Companies, H1 2017 (Contd..5), H1 2017 |
| Products under Development by Universities/Institutes, H1 2017 |
| Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017 |
| Number of Products by Stage and Target, H1 2017 |
| Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017 |
| Number of Products by Stage and Mechanism of Action, H1 2017 |
| Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017 |
| Number of Products by Stage and Route of Administration, H1 2017 |
| Number of Products by Stage and Molecule Type, H1 2017 |
| Osteoporosis - Pipeline by Addex Therapeutics Ltd, H1 2017 |
| Osteoporosis - Pipeline by Alize Pharma SAS, H1 2017 |
| Osteoporosis - Pipeline by Alvogen Korea Co Ltd, H1 2017 |
| Osteoporosis - Pipeline by Amgen Inc, H1 2017 |
| Osteoporosis - Pipeline by Amura Holdings Ltd, H1 2017 |
| Osteoporosis - Pipeline by BiologicsMD Inc, H1 2017 |
| Osteoporosis - Pipeline by Bone Biologics Corp, H1 2017 |
| Osteoporosis - Pipeline by Bristol-Myers Squibb Company, H1 2017 |
| Osteoporosis - Pipeline by Cellmid Ltd, H1 2017 |
| Osteoporosis - Pipeline by ChoDang Pharm Co Ltd, H1 2017 |
| Osteoporosis - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2017 |
| Osteoporosis - Pipeline by Corium International Inc, H1 2017 |
| Osteoporosis - Pipeline by Critical Pharmaceuticals Ltd, H1 2017 |
| Osteoporosis - Pipeline by Daiichi Sankyo Company Ltd, H1 2017 |
| Osteoporosis - Pipeline by ElexoPharm GmbH, H1 2017 |
| Osteoporosis - Pipeline by EndoCeutics Inc, H1 2017 |
| Osteoporosis - Pipeline by Entera Bio Ltd, H1 2017 |
| Osteoporosis - Pipeline by Enteris BioPharma Inc, H1 2017 |
| Osteoporosis - Pipeline by Enzo Biochem Inc, H1 2017 |
| Osteoporosis - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017 |
| Osteoporosis - Pipeline by Gador SA, H1 2017 |
| Osteoporosis - Pipeline by GL Pharm Tech Corp, H1 2017 |
| Osteoporosis - Pipeline by Glide Pharmaceutical Technologies Ltd, H1 2017 |</p>
<table>
<thead>
<tr>
<th>Osteoporosis - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Osteoporosis - Pipeline by Haoma Medica Ltd, H1 2017</td>
</tr>
<tr>
<td>Osteoporosis - Pipeline by Immunovo BV, H1 2017</td>
</tr>
<tr>
<td>Osteoporosis - Pipeline by Immunwork Inc, H1 2017</td>
</tr>
<tr>
<td>Osteoporosis - Pipeline by Intas Pharmaceuticals Ltd, H1 2017</td>
</tr>
<tr>
<td>Osteoporosis - Pipeline by Ipsen SA, H1 2017</td>
</tr>
<tr>
<td>Osteoporosis - Pipeline by Kaken Pharmaceutical Co Ltd, H1 2017</td>
</tr>
<tr>
<td>Osteoporosis - Pipeline by Lead Discovery Center GmbH, H1 2017</td>
</tr>
<tr>
<td>Osteoporosis - Pipeline by Ligand Pharmaceuticals Inc, H1 2017</td>
</tr>
<tr>
<td>Osteoporosis - Pipeline by Lotus Pharmaceutical Co Ltd, H1 2017</td>
</tr>
<tr>
<td>Osteoporosis - Pipeline by Lupin Ltd, H1 2017</td>
</tr>
<tr>
<td>Osteoporosis - Pipeline by Merck &amp; Co Inc, H1 2017</td>
</tr>
<tr>
<td>Osteoporosis - Pipeline by Mereo Biopharma Group Plc, H1 2017</td>
</tr>
<tr>
<td>Osteoporosis - Pipeline by NIBEC, H1 2017</td>
</tr>
<tr>
<td>Osteoporosis - Pipeline by Omeros Corp, H1 2017</td>
</tr>
<tr>
<td>Osteoporosis - Pipeline by Oncobiologics Inc, H1 2017</td>
</tr>
<tr>
<td>Osteoporosis - Pipeline by Osteologix Holdings Plc, H1 2017</td>
</tr>
<tr>
<td>Osteoporosis - Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2017</td>
</tr>
<tr>
<td>Osteoporosis - Pipeline by Pfenex Inc, H1 2017</td>
</tr>
<tr>
<td>Osteoporosis - Pipeline by PhytoHealth Corp, H1 2017</td>
</tr>
<tr>
<td>Osteoporosis - Pipeline by R Pharm, H1 2017</td>
</tr>
<tr>
<td>Osteoporosis - Pipeline by Ribomic Inc, H1 2017</td>
</tr>
<tr>
<td>Osteoporosis - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H1 2017</td>
</tr>
<tr>
<td>Osteoporosis - Pipeline by Shin Poong PharmCo Ltd, H1 2017</td>
</tr>
<tr>
<td>Osteoporosis - Pipeline by Sinil Pharmaceutical Co Ltd, H1 2017</td>
</tr>
<tr>
<td>Osteoporosis - Pipeline by Stelis Biopharma Pvt Ltd, H1 2017</td>
</tr>
<tr>
<td>Osteoporosis - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017</td>
</tr>
<tr>
<td>Osteoporosis - Pipeline by Terpenoid Therapeutics Inc, H1 2017</td>
</tr>
<tr>
<td>Osteoporosis - Pipeline by TSH Biopharm Corporation Ltd, H1 2017</td>
</tr>
<tr>
<td>Osteoporosis - Pipeline by Uni-Bio Science Group Ltd, H1 2017</td>
</tr>
<tr>
<td>Osteoporosis - Pipeline by Viking Therapeutics Inc, H1 2017</td>
</tr>
<tr>
<td>Osteoporosis - Pipeline by Wroclawskie Centrum Badan EIT+ Sp z oo, H1 2017</td>
</tr>
<tr>
<td>Osteoporosis - Pipeline by Yooyoung Pharm Co Ltd, H1 2017</td>
</tr>
<tr>
<td>Osteoporosis - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017</td>
</tr>
</tbody>
</table>
Osteoporosis - Dormant Projects, H1 2017
Osteoporosis - Dormant Projects, H1 2017 (Contd..1), H1 2017
Osteoporosis - Dormant Projects, H1 2017 (Contd..2), H1 2017
Osteoporosis - Dormant Projects, H1 2017 (Contd..3), H1 2017
Osteoporosis - Dormant Projects, H1 2017 (Contd..4), H1 2017
Osteoporosis - Dormant Projects, H1 2017 (Contd..5), H1 2017
Osteoporosis - Dormant Projects, H1 2017 (Contd..6), H1 2017
Osteoporosis - Discontinued Products, H1 2017
Osteoporosis - Discontinued Products, H1 2017 (Contd..1), H1 2017

List of Figures
Number of Products under Development for Osteoporosis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Top 10 Routes of Administration, H1 2017
Number of Products by Stage and Top 10 Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017

Buy This Report

Single License : $ 2000  
Request sample of this report  
Check discount this report

Go For Report

https://www.marketresearchreports.biz/reports/1070423/osteoporosis-pipeline-review-h1-2017-market-research-reports

Office: United States
State Tower, 90 State Street, Suite 700, Albany, NY 12207, United States